IMC Chicago’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.01M Sell
100,300
-55,700
-36% -$515K ﹤0.01% 3895
2026
Q2
$1.31M Sell
156,000
-31,300
-17% -$285K ﹤0.01% 3520
2026
Q1
$1.69M Buy
187,300
+67,100
+56% +$1.06M ﹤0.01% 2744
2025
Q4
$2.19M Buy
120,200
+68,800
+134% +$1.16M ﹤0.01% 2333
2025
Q3
$754K Buy
51,400
+20,700
+67% +$355K ﹤0.01% 2912
2025
Q2
$559K Sell
30,700
-1,200
-4% -$24.5K ﹤0.01% 2800
2025
Q1
$633K Buy
31,900
+16,000
+101% +$277K ﹤0.01% 2534
2024
Q4
$273K Buy
+15,900
New +$299K ﹤0.01% 3008

Other funds holding ADMA

IMC Chicago's ADMA Position: Q3 2026 in Review

IMC Chicago increased its ADMA Biologics (ADMA) stake by 37% in Q3 2026, buying an estimated $151K and bringing the position to 60,382 shares worth $606K. The position accounts for ﹤0.01% of the portfolio, ranked #4466.

IMC Chicago first reported a position in ADMA in Q2 2025 and has held it in 6 quarters since. 330 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • IMC Chicago held 60,382 shares of ADMA Biologics worth $606K as of Q3 2026.
  • IMC Chicago bought 16,290 ADMA Biologics shares in Q3 2026, an estimated $151K.
  • ADMA Biologics made up ﹤0.01% of IMC Chicago's portfolio in Q3 2026, its #4466 holding.
  • IMC Chicago first reported a position in ADMA Biologics in Q2 2025 and has held it in 6 quarters since.
  • 330 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.